These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 26400304

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.
    Kim DJ, Lee MH, Park TI, Bae HI.
    J Korean Med Sci; 2006 Feb; 21(1):81-5. PubMed ID: 16479070
    [Abstract] [Full Text] [Related]

  • 3. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.
    Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J.
    Cancer; 1997 Apr 15; 79(8):1581-6. PubMed ID: 9118042
    [Abstract] [Full Text] [Related]

  • 4. Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection.
    Takeshima Y, Amatya VJ, Daimaru Y, Nakayori F, Nakano T, Inai K.
    Hum Pathol; 2001 Nov 15; 32(11):1203-8. PubMed ID: 11727259
    [Abstract] [Full Text] [Related]

  • 5. Two types of primary mucinous ovarian tumors can be distinguished based on their origin.
    Simons M, Simmer F, Bulten J, Ligtenberg MJ, Hollema H, van Vliet S, de Voer RM, Kamping EJ, van Essen DF, Ylstra B, Schwartz LE, Wang Y, Massuger LF, Nagtegaal ID, Kurman RJ.
    Mod Pathol; 2020 Apr 15; 33(4):722-733. PubMed ID: 31695154
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D, Hirschmann A, Löhrs U, Diebold J.
    Gynecol Oncol; 2006 Dec 15; 103(3):883-7. PubMed ID: 16806438
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.
    Tafe LJ, Muller KE, Ananda G, Mitchell T, Spotlow V, Patterson SE, Tsongalis GJ, Mockus SM.
    Am J Pathol; 2016 Mar 15; 186(3):671-7. PubMed ID: 26797085
    [Abstract] [Full Text] [Related]

  • 10. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary.
    Griffiths AP, Cross D, Kingston RE, Harkin P, Wells M, Quirke P.
    Int J Gynecol Pathol; 1993 Oct 15; 12(4):307-14. PubMed ID: 8253547
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Expression and significance of p-AKT, p-GSK3β and β-catenin in epithelial carcinoma of ovary].
    Wei X, Lü QJ, Sun HX, Qi YF, Wang JO, Cao CC.
    Zhonghua Bing Li Xue Za Zhi; 2012 Feb 15; 41(2):86-90. PubMed ID: 22455883
    [Abstract] [Full Text] [Related]

  • 13. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
    Zhang YL, Guo XR, Shen DH, Cheng YX, Liang XD, Chen YX, Wang Y.
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan 15; 41(1):33-8. PubMed ID: 22455848
    [Abstract] [Full Text] [Related]

  • 14. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.
    Lee YJ, Lee MY, Ruan A, Chen CK, Liu HP, Wang CJ, Chao WR, Han CP.
    Oncotarget; 2016 Dec 13; 7(50):82097-82103. PubMed ID: 27888800
    [Abstract] [Full Text] [Related]

  • 15. Expression of REG4 in ovarian mucinous tumors.
    Huang Q, Chen X, Lu W, Lai M, Lu B.
    Appl Immunohistochem Mol Morphol; 2014 Apr 13; 22(4):295-301. PubMed ID: 23958547
    [Abstract] [Full Text] [Related]

  • 16. Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints.
    Versa-Ostojić D, Stanković T, Stemberger-Papić S, Vrdoljak-Mozetic D, Manestar M, Krasević M.
    Anal Quant Cytol Histol; 2008 Jun 13; 30(3):160-8. PubMed ID: 18630841
    [Abstract] [Full Text] [Related]

  • 17. Mutations in the KRAS gene in ovarian tumors.
    Dobrzycka B, Terlikowski SJ, Kowalczuk O, Niklińska W, Chyczewski L, Kulikowski M.
    Folia Histochem Cytobiol; 2009 Jun 13; 47(2):221-4. PubMed ID: 19995707
    [Abstract] [Full Text] [Related]

  • 18. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS.
    BMC Cancer; 2015 May 19; 15():415. PubMed ID: 25986173
    [Abstract] [Full Text] [Related]

  • 19. C-myc oncogene product P62c-myc in ovarian mucinous neoplasms: immunohistochemical study correlated with malignancy.
    Polacarz SV, Hey NA, Stephenson TJ, Hill AS.
    J Clin Pathol; 1989 Feb 19; 42(2):148-52. PubMed ID: 2921356
    [Abstract] [Full Text] [Related]

  • 20. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
    Hu YQ, Liu YJ.
    Ai Zheng; 2005 Jan 19; 24(1):104-9. PubMed ID: 15642212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.